Delivery Order SPE2DB20D3101-SPE2DB25FRWA2
- Not listed
- The Defense Logistics Agency awarded a $2,172.80 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen/ml on September 22, 2025, with completion expected by September 23, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody used for migraine prevention, indicating this order supports the federal government's...
- The Defense Logistics Agency awarded a $5,864.45 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on September 4, 2025, with completion targeted for September 5, 2025. This non-competitive delivery order represents a firm fixed price transaction under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Emgality 120 mg/mL pen injectors, valued at $1,556.10. This is a firm fixed-price delivery order with an ultimate completion date of August 29, 2025, and represents a non-competitive set-aside award. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Emgality 120 mg/ml pen injectors, with a ceiling value of $1,527.12. This is a firm fixed price delivery order with an ultimate completion date of September 30, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pens on September 11, 2025, with a ceiling value of $1,037.40 under a firm fixed price contract type. This order represents a non-competitive set-aside delivery against AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,530.62 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of September 17, 2025. This competitive award uses firm fixed pricing with no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,401.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen (injectable migraine treatment) with a completion date of September 17, 2025. This competitively awarded, firm fixed-price delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The contract specifies performance at the company's Conshohocken, Pennsylvania facility, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Emgality 120 mg/ml pen injectors, valued at $3,458.00. This firm fixed-price contract, which is non-set-aside and competitively awarded, is scheduled for completion by August 7, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pens on June 13, 2025. This contract, issued on a firm fixed-price basis with an ultimate completion date of June 16, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major pharmaceutical distributor providing critical medical supplies to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Emgality 120 mg/mL pen injectors, with a ceiling value of $1,037.40. This firm fixed-price delivery order, which is not set-aside, is scheduled for completion by September 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody indicated for migraine prevention, representing a...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRWA2Delivery Order
The Defense Logistics Agency awarded a $8,299.20 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pens on September 22, 2025, with an ultimate completion date of September 23, 2025. This non-competitive, firm fixed-price delivery order represents a small-value pharmaceutical procurement fulfilling federal medical supply requirements. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for the federal government's military and veteran healthcare systems through its extensive portfolio of brand-name and generic medications, vaccines, and medical supplies. This delivery order is issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Emgality, a CGRP monoclonal antibody indicated for migraine prevention, represents one of the specialized medications delivered through this strategic contract vehicle to support Defense Health Agency and other government healthcare system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.3k | 9/22/25 |